Evidence map›Paper›PMID 40622478›Full record

ArticleInternational journal of clinical oncology2025

Celecoxib has less aggravating effect on cisplatin-induced nephrotoxicity in comparison with non-selective cyclooxygenase inhibitors: a retrospective multi-institutional study.

Keisuke Okamoto, Yoshitaka Saito, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Katsuya Narumi, Mitsuru Sugawara, Masaki Kobayashi

Abstract readMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Keisuke OkamotoFaculty of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Hokkaido University, Kita-12-Jo, Nishi-6-Chome, Kita-Ku, Sapporo, 060-0812, Japan.
Yoshitaka SaitoFaculty of Pharmaceutical Sciences, Department of Clinical Pharmaceutics and Therapeutics, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Chome, Teine-Ku, Sapporo, 006-8585, Japan. yossypma@med.hokudai.ac.jp.
Kenta TakahashiDepartment of Pharmacy, NTT Medical Center Sapporo, Minami 1-Jo, Nishi 15-Chome, Chuo-Ku, Sapporo, 060-0061, Japan.
Yoh TakekumaDepartment of Pharmacy, Hokkaido University Hospital, Kita-14-Jo, Nishi-5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
Jun Sakakibara-KonishiFaculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Kita 15-Jo, Nishi 7-Chome, Kita-Ku, Sapporo, 060-8638, Japan.
Katsuya NarumiFaculty of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Hokkaido University, Kita-12-Jo, Nishi-6-Chome, Kita-Ku, Sapporo, 060-0812, Japan.
Mitsuru SugawaraDepartment of Pharmacy, Hokkaido University Hospital, Kita-14-Jo, Nishi-5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
Masaki KobayashiFaculty of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Hokkaido University, Kita-12-Jo, Nishi-6-Chome, Kita-Ku, Sapporo, 060-0812, Japan. masaki@pharm.hokudai.ac.jp.ORCID http://orcid.org/0000-0003-3762-2391

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin (CDDP)-induced nephrotoxicity (CIN) is one of its most serious adverse effects. Although we previously demonstrated that celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, attenuates CIN in a basic study, there are no reports that have evaluated its clinical impact on CIN. Therefore, we aimed to determine the effect of celecoxib on CIN compared with that of non-selective COX inhibitors.

methodsPatients with lung cancer receiving CDDP (≥ 60 mg/m

resultsCIN occurred in 24.2% of patients in the COX-1 group (n = 33) and 0% of those in the celecoxib group (n = 15) in all cycles, showing a significant difference (P = 0.04). In addition, the variance in CCr was significantly smaller in the celecoxib group than in the COX-1 group in all cycles, as well as at the primary endpoint (P = 0.02). However, there was no difference in the incidence of CIN or variance in CCr in the first cycle between the two groups. The incidences of nausea, vomiting, and anorexia were similar between the groups, implying a similar amount of oral hydration.

conclusionThese findings suggest that celecoxib is less aggravating on CIN than non-selective COX inhibitors.

Indexed as

CelecoxibCisplatinCyclooxygenase InhibitorsKidney DiseasesLung NeoplasmsAdultAgedAntineoplastic AgentsFemaleHumansMaleMiddle AgedNaproxenPhenylpropionatesRetrospective StudiesAntineoplastic AgentsCelecoxibCisplatinCyclooxygenase InhibitorsloxoprofenNaproxenPhenylpropionatesCelecoxibCisplatinInduced nephrotoxicityLoxoprofenNaproxenNon-selective cyclooxygenase inhibitorsNon-steroidal anti-inflammatory drugs

Identifiers

PMID40622478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.